

B68

Priority Applications (No Type Date): JP 9440326 A 19940131

Patent Details:

Patent No Kind Lan Pg Main IPC Filing Notes
JP 7216000 A 8 C07K-016/28

Abstract (Basic): JP 7216000 A

Combined prod. of a monoclonal antibody against epithelium growth factor (EGF) receptor, consists of the monoclonal antibody against EGF receptor and a spacer.

Also claimed are (A) a complex of a monoclonal antibody against EGF receptor in which monoclonal antibody against EGF receptor is combined to gene via spacer or directly, (B) method for introduction of the complex into a cell through an EGF receptor, (C) prepn. of a combined prod. of a monoclonal antibody against EGF receptor in which the monoclonal antibody against EGF receptor is combined to a spacer, and (D) prepn. of a complex of a monoclonal antibody against EGF receptor in which the monoclonal antibody against EGF receptor is combined to a gene through a spacer or directly.

ADVANTAGE - Combined prod. and complex can recognise only cells producing EGF receptor as target. Method can introduce any gene to a cell.

In an example, IgG2 mouse monoclonal antibody immunologically reacting with low affinity EGF receptor was prepd. by a hybridoma cell line. Thus, BALB/c mouse spleen cell immunised by human carcinoembryonic antigen (CEA) was fused with mouse myeloma cell. Hybridoma sub-clone was cultured and IgG obtd. from cell was purified by ammonium sulphate pptn. and a DEAE Cellulose column. Resultant monoclonal antibody was confirmed to be IgG. It was modified by dithiopyridyl gps. Polylysine was modified by 2-iminothiorane. Modified monoclonal antibody was combined to the modified polylysine. The combined prod/DNA complex was prepd.

Dwg.0/4

? S PN=JP 57163318

S6 1 PN=JP 57163318

? T 6/3,AB/1

6/3,AB/1

DIALOG(R)File 351:Derwent WPI

(c) 2003 Thomson Derwent. All rts. reserv.

003550275

WPI Acc No: 1982-98272E/*198246*

Human beta-interferon antigen prepn. - by reacting N-terminal peptide of interferon with carrier in presence of hapten-carrier binder

Patent Assignee: OTSUKA PHARM CO LTD (SAKA)

Number of Countries: 001 Number of Patents: 001

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
JP 57163318	A	19821007				198246 B

Priority Applications (No Type Date): JP 8147841 A 19810331

Patent Details:

Patent No Kind Lan Pg Main IPC Filing Notes
JP 57163318 A 23

Abstract (Basic): JP 57163318 A

Prodn. of human beta-interferon antigen (I) comprises reacting an

N-terminal peptide R-Leu-Gln-Arg-Ser-Ser-OH (II) of human beta-interferon as a hapten with a carrier in the presence of a hapten-carrier binding agent, to give a peptide-carrier complex. In (II) is H, H-Phe-, H-Leu-Gly-Phe-, H-Tyr-Asn-Leu-Leu-Gly-Phe- or H-Met-Ser-Tyr-Asn-Leu-Gly-Phe-. (I) is useful in obtaining human beta-interferon antibody in high specificity.

The peptide (II) is linked to a carrier in the presence of a hapten-carrier binding agent. Examples of the carrier are horse serum albumin, bovine serum albumin, rabbit serum albumin, human serum albumin, ovine serum albumin, horse serum globulin, bovine serum globulin, rabbit serum globulin, ovine hemoglobin, animal hemocyanine, a protein extract from Ascaris, polylysine, polyglutamic acid, lysine-glutamic acid copolymer and lysine-ornithine copolymer. As the hapten-carrier binding agent are mentioned aliphatic dialdehydes (e.g. glyoxal, malondialdehyde, glutaraldehyde, succinaldehyde, adipaldehyde), N,N'-o-phenylenedimaleimide, m-maleimidobenzoyl-N-hydroxysuccinimide ester, N,N-dicyclohexyl carbodiimide, N-ethyl-N'-dimethylaminocarbodiimide, 1-ethyl-3-diisopropylamino carbodiimide, 1-cyclohexyl-3-(2-morpholinyl-4-ethyl) carbodiimide, etc. The reaction is effected in water or a buffer at 0-40 deg.C. within a pH range of 7-10 for 1-24

? S PN=JP 58225028

S7 1 PN=JP 58225028

? T 7/3,AB/1

7/3,AB/1

DIALOG(R)File 351:Derwent WPI

(c) 2003 Thomson Derwent. All rts. reserv.

003888691

WPI Acc No: 1984-034233/*198406*

XRAM Acc No: C84-014549

Human alpha-interferon antibody prepn. - by injecting alpha-interferon antigen into animal

Patent Assignee: OTSUKA PHARM CO LTD (SAKA)

Number of Countries: 001 Number of Patents: 002

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
JP 58225028	A	19831227	JP 82110470	A	19820625	198406 B
JP 92053880	B	19920827	JP 82110470	A	19820625	199239

Priority Applications (No Type Date): JP 82110470 A 19820625

Patent Details:

Patent No Kind Lan Pg Main IPC Filing Notes

JP 58225028 A 14

JP 92053880 B 92 C07K-015/14 Based on patent JP 58225028

Abstract (Basic): JP 58225028 A

Human alpha-interferon antigen comprising complex of C-terminal peptide of human lymphoblastoid interferon of formula R-Ser-Leu-Ser-Thr-Asn-Gln-Clu -Ser-Leu-Arg-Ser-Lys-Glu-OH (where R is H or H-Tyr-) or its derivative thereof, and carrier, is dosed to mammal, and the formed antigen is taken out.

Antibody is specifically reactive to human alpha-interferons (I), and is used for determ. of (I) by radioimmunoassay or enzyme-immunoassay or for purificn. of (I) by affinity-chromatography